Webinar Registration

Sona recently announced promising pre-clinical interim study results on the use of its cancer therapy together with interleukin-2, a common immunotherapy agent, that revealed a synergistic effect in triple negative breast cancer mouse models. These webinars will provide an overview of the study’s first phase of findings on Sona’s ‘Targeted Hyperthermia Therapy’ mechanism, highlighting its potential for shrinking tumors and better enabling immunotherapies, with minimal collateral damage to surrounding healthy tissues. The webinars will features the study’s Principal Investigator, Dr. Carman Giacomantonio, Sona’s Chief Scientific Officer, Len Pagliaro PhD and Sona CEO, David Regan.